9430 Key West Avenue
5 articles with Cellphire
Cellphire Therapeutics, Inc., a biotechnology company developing next-generation platelet-based hemostatic therapeutics for application across multiple medical indications, announced today that Michael Gaffney has joined the company as Chief Executive Officer, effective immediately.
Cellphire Therapeutics, Inc., the global leader in long-term stabilization and storage of platelets, announced today the close of a $15 million Series A financing round led by Simcah Management.
Cellphire Announces Orphan Drug Designation of Thrombosomes® for Treatment of Acute Radiation Syndrome
Cellphire, the global leader in long-term stabilization and storage of platelets, announced today that the U.S. Food and Drug Administration (FDA) has granted an orphan drug designation for its platelet-based freeze-dried hemostatic, Thrombosomes®, for treatment of acute radiation syndrome (ARS).
Cellphire, Inc. announced that the Biomedical Advanced Research and Development Authority, part of the office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, has exercised its third contract option valued at $33.3 million to support Cellphire's next generation platelet-based hemostatic product, Thrombosomes®, through a Phase 2 clinical trial in bleeding thrombocytopenic patients.
Under the contract, Cellphire will perform all research, development, manufacturing, and regulatory activities.